Zollinger-Ellison syndrome medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 15: | Line 15: | ||
*[[H2-receptor antagonist]]s | *[[H2-receptor antagonist]]s | ||
:*[[Famotidine]] | :*[[Famotidine]] | ||
:*[[Ranitidine]] | :*[[Ranitidine]] | ||
*[[Chemotherapy]] | *[[Chemotherapy]] | ||
:* Used for tumors that can not be surgically resected | :* Used for tumors that can not be surgically resected | ||
Revision as of 22:32, 17 July 2017
|
Zollinger-Ellison syndrome Microchapters |
|
Differentiating Zollinger-Ellison syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Zollinger-Ellison syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Zollinger-Ellison syndrome medical therapy |
|
Risk calculators and risk factors for Zollinger-Ellison syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Mohamad Alkateb, MBBCh [2]
Overview
Pharmacologic medical therapies for Zollinger-Ellison syndrome include proton pump inhibitors, H2-receptor antagonists, chemotherapy, and hormonal therapy.
Medical Therapy
Medical therapy for Zollinger-Ellison syndrome may includes the following:[1]
- Omeprazole 60 mg per day
- Esomeprazole 120 mg per day
- Lansoprazole 45 mg per day [2]
- Rabeprazole] 60 mg per day
- Pantoprazole 120 mg per day [3]
- Used for tumors that can not be surgically resected
- Streptozotocin
- 5-fluorouracil
- Doxorubicin
- Octreotide can be used to slow down acid secretion
References
- ↑ Zollinger-Ellison syndrome 2015.https://en.wikipedia.org/wiki/Zollinger%E2%80%93Ellison_syndrome
- ↑ Hirschowitz BI, Simmons J, Mohnen J (2005). "Clinical outcome using lansoprazole in acid hypersecretors with and without Zollinger-Ellison syndrome: a 13-year prospective study". Clin Gastroenterol Hepatol. 3 (1): 39–48. PMID 15645403.
- ↑ Metz DC, Comer GM, Soffer E, Forsmark CE, Cryer B, Chey W; et al. (2006). "Three-year oral pantoprazole administration is effective for patients with Zollinger-Ellison syndrome and other hypersecretory conditions". Aliment Pharmacol Ther. 23 (3): 437–44. doi:10.1111/j.1365-2036.2006.02762.x. PMID 16423003.